• The Journal of Internal Korean Medicine
• /
• v.41 no.3
• /
• pp.424-433
• /
• 2020

Qingfei Paidu decoction is recommended for treatment and prevention of COVID-19. It is a prescription that combines Mahaenggamseok-tang, Oryeong-san, Soshiho-tang, Saganmahwang-tang, and Kwakhyangjeonggi-san. According to several clinical reviews, symptoms of COVID-19 were improved, laboratory test indicators were improved, and the cure rate was increased. Pharmacologically, the Qingfei Paidu decoction and its composition have been reported to inhibit viral replication, alleviate immune responses, and have anti-inflammatory and antiviral effects. Severe side effects were not revealed, and this treatment is considered relatively safe. However, to validate and better understand these findings, well-designed clinical studies are needed.

• The Journal of Internal Korean Medicine
• /
• v.43 no.2
• /
• pp.264-273
• /
• 2022

The purpose of this report is to describe the effects of Qingfei Paidu decoction (QPD) and QPD without Ephedra Herba on COVID-19 patients. One COVID-19 patient was treated with QPD and two others who had been sensitive to ephedra were treated with QPD without it. The fever, cough, and sore throat of all three were monitored three times a day through non-face-to-face assessment for a total of five to seven days, and cough and throat pain changes were evaluated with a numeric rating scale (NRS). After treatment, the fever and NRS scores were improved for all three patients. These results indicate that both QPD and QPD without Ephedra Herba is an effective treatment for COVID-19 symptoms.

• The Journal of Korean Medicine
• /
• v.44 no.4
• /
• pp.41-58
• /
• 2023

Objectives: This retrospective observational study aimed to investigate the efficacy and safety of Cheongpebaedok-tang, a traditional Korean herbal medicine, provided via telemedicine to patients with asymptomatic to mild COVID-19 in Korea. Methods: From February to April 2020, a retrospective analysis investigated COVID-19 patients treated via Korean telemedicine. The study involved asymptomatic to mild cases receiving Cheongpebaedok-tang more than three times, along with continuous Korean medicine care in convalescence. Diagnoses and treatment adhered to the telemedicine guidelines of the Association of Korean Medicine, with varied Cheongpebaedok-tang prescriptions based on symptom severity. Symptom evaluation involved a detailed assessment using a 15-item tool at initial and final sessions. Results: The study included 27 patients, with a mean age of 48.7 ± 2.3 years (mean ± standard error). Patients began self-administering oral Cheongpebaedok-tang for an average of 19.4 ± 1.8 days after the date of COVID-19 diagnosis confirmation and continued the medication for 15.8 ± 1.2 days. The reported side effects of the Cheongpebaedok-tang included palpitations (11.1%), insomnia (7.4%), dizziness (3.7%), and diarrhea (3.7%). All side effects disappeared after adjusting the prescription according to standard treatment guidelines. The occurrence of all COVID-19-related adverse symptoms, except fatigue and myalgia, decreased. Fatigue was the most common chronic symptom persisting after 6 months (51.9%), followed by ocular symptoms (37.0%) and sore throat (22.2%). Conclusions: This study implies Cheongpebaedok-tang may offer a potentially safe, symptom-alleviating approach for managing mild COVID-19 cases via telemedicine, although further comprehensive research is warranted.